PDCD1 and neoplasm: The post-trastuzumab tumor showed high immune activation with distinct nuclear staining of NF-κB/p65RelA in the majority of tumor cells alongside a higher number of CD4+ and CD8+ cells, and numerous immune cells expressing PD-1 (Figure 5I–L).